|
Miraculins Inc., a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce that Mr. Eric Johnstone, CA has been appointed as Chief Financial Officer.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce that it will be presenting at AACR-NCI-EORTC International Conference: “Molecular Targets and Cancer Therapeutics” to be held on October 22 - 26, 2007, in San Francisco, CA.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to update the Company’s shareholders on its prostate cancer diagnostic.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce that it will be presenting at BioContact Quebec 2007 in Quebec City.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, has closed its previously announced private placement with aggregate gross proceeds to the Company of $428,000 from the sale of 1,222,858 units at a price of $0.35 per Unit.
Read More
|
|
|